– USA, MA – PureTech Health plc (Nasdaq: PRTC / LON: PRTC), a clinical-stage biotherapeutics company dedicated to changing the lives of patients with devastating diseases, today announced the appointment of Dr. Michele Holcomb (PhD) to its Board as independent non-executive director with effect as of September 23, 2024, bringing more than 30 years of expertise leading global healthcare companies through strategic inflection points and preparing innovative programs and portfolios for growth.
“I am honored to welcome Dr. Holcomb to our organization,” said Board chair, Dr. Raju Kucherlapati. “Dr. Holcomb’s extensive background in biopharma, coupled with her innovative mindset and unwavering dedication to excellence, positions her as a pivotal addition to our board. Her unique insights and strategic vision will be instrumental as we work to advance our company’s mission, and I am confident that her contributions will drive significant value not only for patients but also for our shareholders.”
Dr. Holcomb will also join the Audit Committee.
About Dr. Michele Holcomb
Dr. Michele Holcomb is a strategic leader with more than 30 years of healthcare experience across biotech, pharmaceuticals, and healthcare services. She has served on both public and private boards and has been a scientist, consultant, and executive, driving change through innovation and optimization at key interfaces. In her previous role as EVP, CCSBDO at Cardinal Health, Dr. Holcomb leveraged an enterprise perspective and knowledge of the evolving healthcare landscape to work with the CEO, CFO, and leaders across the Pharmaceutical and Medical segments to define strategies, optimize the portfolio, and identify growth and innovation opportunities. Her team also led the execution and integration of investments, acquisitions, partnerships, and divestitures to support Cardinal Health’s strategy, as well as drove the enterprise approach to innovation.
“PureTech pioneered the hub-and-spoke business model, and its approach successfully combines commercial, scientific and medical expertise towards a highly focused development strategy for each of the therapies in its portfolio,” said Dr. Michele Holcomb. “I am excited and honored to work with my fellow board members and the PureTech management team to guide the Company through the next stage of evolution.”
Before Cardinal Health, Dr. Holcomb was COO of Global R&D and SVP of Strategy, Portfolio, Search, and Partnerships at Teva Pharmaceuticals. She also spent 15 years at McKinsey & Company and was a Partner of the Global Pharmaceutical Practice. Dr. Holcomb is a member of the board of directors and chair of the Nominating and ESG (NESG) committee of Kimball Electronics Inc (Nasdaq: KE). She also serves on the board of the Abigail Wexner Research Institute at Nationwide Children’s Hospital in Columbus, the BalletMet of Columbus, where she chairs the long-range planning committee, and the Liberty Science Center in New Jersey. Dr. Holcomb is a member of the editorial advisory board of Pharmaceutical Executive and has lectured on healthcare strategy at Kellogg (Northwestern), Columbia, and Fuqua (Duke) business schools. Dr. Holcomb received a BS in chemistry from Stanford University and a PhD in chemistry from the University of California, Berkeley, and previously worked as an R&D chemist at Ciba-Geigy and Syntex Pharmaceuticals.
About PureTech Health
PureTech is a clinical-stage biotherapeutics company dedicated to giving life to new classes of medicine to change the lives of patients with devastating diseases. The Company has created a broad and deep pipeline through its experienced research and development team and its extensive network of scientists, clinicians, and industry leaders that is being advanced both internally and through its Founded Entities. PureTech’s R&D engine has resulted in the development of 29 therapeutics and therapeutic candidates, including two that have received both U.S. FDA clearance and European marketing authorization and a third that has been filed for FDA approval. A number of these programs are being advanced by PureTech or its Founded Entities in various indications and stages of clinical development, including registration-enabling studies. All of the underlying programs and platforms that resulted in this pipeline of therapeutic candidates were initially identified or discovered and then advanced by the PureTech team through key validation points.
For more: https://puretechhealth.com/
- Disclaimer - News, data, and statements included in this release are intended exclusively for general information purposes. Talent4Boards does not guarantee that news is accurate or about the correct person and accepts neither liability for the consequences of the reader’s reliance, nor responsibility for the accuracy of the information. Nothing in this release should be considered for decisions about referred securities. Products and brand names may be trademarks or registered trademarks of their respective owners.